Medicinova Inc

NASDAQ:MNOV   10:36:22 AM EDT
3.72
-0.01 (-0.27%)
Earnings Announcements

Medicinova Announces Positive Results From Phase 2 Trial Of Mn-166 (Ibudilast) In Alcohol Use Disorder Published In Nature’S Translational Psychiatry Journal

Published: 06/21/2021 11:48 GMT
Medicinova Inc (MNOV) - Medicinova Announces Positive Results From Phase 2 Trial of Mn-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal.
Medicinova Inc - Key Results Reported in Publication Include Ibudilast Did Not Have a Significant Effect on Negative Mood.
Medicinova Inc - Key Results Reported in Publication Include Ibudilast, Relative to Placebo, Reduced Odds of Heavy Drinking Across Time by 45%.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.09

More details on our Analysts Page.